New NAFLD drug safety checked in patients with liver damage

NCT ID NCT05917938

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a single injection of a new drug (NNC0194-0499) for non-alcoholic fatty liver disease in 33 people with various degrees of liver impairment and healthy volunteers. The goal was to see how the liver processes the drug and whether it is safe. Results will help determine the right dose for future studies in patients with liver problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0194-0499
What this could lead to: If successful, this study will help doctors decide the right dose of this NAFLD drug for patients with liver problems, making future treatments safer.
What could go wrong: This is a very early, small study (33 people) focused on safety and drug levels, not on whether the drug works. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEPATIC IMPAIRMENT

Contacts and locations

Locations

APEX Research

München, 81241, Germany
Cardiomedicum Sp. z o.o.

Krakow, 30-002, Poland
Summit Clinical Research s.r.o.

Bratislava, 83101, Slovakia
Summit Clinical Research s.r.o.

Malacky, 901 22, Slovakia
Uniwersyteckie Centrum Kliniczne (UCK)

Gdansk, 80-214, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.